FOCL logo

EDAP TMS S.A. (FOCL)

$2.84

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on FOCL

Market cap

$134106473

EPS

-0.27

P/E ratio

--

Price to sales

5.35

Dividend yield

--

Beta

-0.013472

Price on FOCL

Previous close

$3.17

Today's open

$2.96

Day's range

$2.80 - $3.12

52 week range

$1.95 - $6.40

Profile about FOCL

CEO

Ryan Rhodes

Employees

289

Headquarters

Vaulx-en-Velin,

Exchange

NASDAQ Global Market

Shares outstanding

47220589

Issue type

American Depository Receipt

FOCL industries and sectors

Healthcare

Medical Distributors

News on FOCL

EDAP TMS S.A. (FOCL) Presents at 2026 UBS Global Healthcare Conference Transcript

EDAP TMS S.A. ( FOCL ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Presentation Unknown Analyst Welcome, everybody.

news source

Seeking Alpha • Nov 10, 2026

news preview

EDAP TMS S.A. (FOCL) Q3 2026 Earnings Call Transcript

EDAP TMS S.A. ( FOCL ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Conference Call Participants Louisa Smith - Gilmartin Group LLC Alexander Nowak - Lucid Capital Markets, LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Presentation Operator Greetings, and welcome to the FocalTherics Third Quarter 2026 Conference Call.

news source

Seeking Alpha • Nov 8, 2026

news preview

FocalTherics Q3 Earnings Call Highlights

FocalTherics NASDAQ: FOCL reported 26% growth in third-quarter 2026 revenue from its high-intensity focused ultrasound business, but lowered the top end of its full-year forecast after three anticipated system sales slipped into the fourth quarter.

news source

MarketBeat • Nov 6, 2026

news preview

FocalTherics™ Reports Third Quarter 2026 Financial Results

FocalTherics™ Reports Third Quarter 2026 Financial Results 45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”1), a global leader in robotic focal therapy, today announced financial results for the third quarter of 2026. Third Quarter 2026 Results and Recent Highlights Increased Revenue to $9.8 million, a 26% Increase Compared to the Prior Year Period 32% Increase in U.S. Procedure Volume over the Prior Year Period Recorded Seven Focal One® Capital System Sales compared to Six in the Prior Year Period, Expanded Focal One System Installed Base to 192, including 98 in the U.S. and 94 Internationally Increased Gross Margin to 51.4%, Compared to 46.6% in the Prior Year Period Expanded Commercial Focal One Endometriosis Programs to Three Centers in Europe Positive Coverage Policies Published by Major Commercial Payers for HIFU in Radiorecurrent Prostate Cancer “We demonstrated steady commercial momentum in the third quarter, highlighted by expanding adoption across multiple new regions and additional system sales in the United States, Turkey, Mexico, and France,” said Ryan Rhodes, CEO of FocalTherics.

news source

GlobeNewsWire • Nov 5, 2026

news preview

FocalTherics™ to Participate in Upcoming Investor Conferences

FocalTherics ™ to Participate in Upcoming Investor Conferences

news source

GlobeNewsWire • Nov 4, 2026

news preview

FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026

Company to host conference call and webcast on Thursday, November 5 at 4:30 p.m. ET Company to host conference call and webcast on Thursday, November 5 at 4:30 p.m. ET

news source

GlobeNewsWire • Oct 22, 2026

news preview

FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference

FocalTherics ™ to Present at the H.C. Wain w right 28 th Annual Global Investment Conference Company to Present and Host 1x1 Investor Meetings on T uesday and Wednesday, September 15 th -16 th , 2026 AUSTIN, Texas, Sept.

news source

GlobeNewsWire • Sep 1, 2026

news preview

FocalTherics Q2 Earnings Call Highlights

FocalTherics NASDAQ: FOCL reported second-quarter HIFU revenue of $13.2 million, up 39% from $9.5 million a year earlier, as the company continued to expand sales of its Focal One high-intensity focused ultrasound platform for focal therapy.

news source

MarketBeat • Aug 14, 2026

news preview

EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript

EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 14, 2026

news preview

FocalTherics™ Reports Second Quarter 2026 Financial Results

FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial results for the second quarter of 2026. This marks the Company's first reporting period presenting its HIFU business as continuing operations and its ESWL and Distribution businesses as discontinued operations.

news source

GlobeNewsWire • Aug 13, 2026

news preview

¹ Disclosures

Get started with M1

Invest in EDAP TMS S.A.

Open an M1 investment account to buy and sell EDAP TMS S.A. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in FOCL on M1